We are live on ! Find out more
TRDA icon

Entrada Therapeutics
TRDA

33 hedge funds and large institutions have $386M invested in Entrada Therapeutics in 2022 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 7

28% more capital invested

Capital invested by funds: $302M → $386M (+$84.5M)

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

0.83% less ownership

Funds ownership: 78.99% → 78.15% (-0.83%)

13% less funds holding

Funds holding: 38 → 33 (-5)

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

Holders
33
Holders Change
-5
Holders Change %
-13.16%
% of All Funds
0.57%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.09%
New
4
Increased
14
Reduced
7
Closed
9
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$6.79M
2
SG
StepStone Group
California
+$1.6M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$1.37M
4
Invesco
Invesco
Georgia
+$1.21M
5
BlackRock
BlackRock
New York
+$1.05M

Top Sellers

Rank Fund Capital Flow
1
Wellington Management Group
Wellington Management Group
Massachusetts
-$6.71M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$5.6M
3
CA
CHI Advisors
New York
-$1.99M
4
SCM
Suvretta Capital Management
New York
-$1.29M
5
Millennium Management
Millennium Management
New York
-$932K
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$63K -$115K -9,025 -69%
TRCT
27
Tower Research Capital (TRC)
New York
$40K +$31.8K +2,508 New
Citigroup
28
Citigroup
New York
$25K +$18.9K +1,489 +1,584%
Barclays
29
Barclays
United Kingdom
$19K +$15K +1,179 +3,275%
CSS
30
Cubist Systematic Strategies
Connecticut
$16K -$11K -869 -46%
Osaic Holdings
31
Osaic Holdings
Arizona
$5K – – –
BNP Paribas Financial Markets
32
BNP Paribas Financial Markets
France
$3.12K +$2.51K +198 New
Wells Fargo
33
Wells Fargo
California
$3K +$660 +52 +46%
CA
34
CHI Advisors
New York
– -$1.99M -163,496 Closed
SCM
35
Suvretta Capital Management
New York
– -$1.29M -106,000 Closed
Millennium Management
36
Millennium Management
New York
– -$932K -76,498 Closed
E
37
Ergoteles
New York
– -$229K -18,807 Closed
Citadel Advisors
38
Citadel Advisors
Florida
– -$158K -12,947 Closed
OWP
39
Old Well Partners
North Carolina
– -$155K -12,700 Closed
UBS Group
40
UBS Group
Switzerland
– -$8K -597 Closed
New York State Common Retirement Fund
41
New York State Common Retirement Fund
New York
– -$1K -109 Closed
1
2

TRDA Hedge Fund Activity: Q3 2022 in Review

33 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Entrada Therapeutics (TRDA) for Q3 2022, worth a combined $386M — up 28% from $302M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of TRDA and 4 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 14 added.

The largest buyer was T. Rowe Price Associates, adding an estimated $6.79M. The largest seller was Wellington Management Group, cutting an estimated $6.71M.

  • 33 institutional investors held Entrada Therapeutics (TRDA) as of Q3 2022, down from 38 in Q2 2022.
  • Funds reported $386M of Entrada Therapeutics stock for Q3 2022, up 28% quarter-over-quarter.
  • 4 funds opened new Entrada Therapeutics positions in Q3 2022 and 9 closed out, a net change of -5 holders.
  • The largest Entrada Therapeutics buyer in Q3 2022 was T. Rowe Price Associates, an estimated $6.79M added.
  • The largest Entrada Therapeutics seller in Q3 2022 was Wellington Management Group, an estimated $6.71M sold.

Based on aggregated 13F filings for Q3 2022.